CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 38 enrolled
Drug / intervention
Aripiprazole +1 moredrug
Likely dose
Aripiprazole 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01188668
NCT01188668Phase 4Completed
CompareCT.gov

An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Aripiprazole When Coadministered In Healthy Subjects

Pfizer·interventional·Posted Aug 25, 2010·Updated Nov 7, 2011

In Brief

A Phase 4 clinical trial evaluating Aripiprazole and Aripiprazole + desvenlafaxine succinate sustained release for Pharmacokinetics and 2 related conditions. Completed, enrolled 38 participants across 2 sites.

Detailed Summary

The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects. This study will also evaluate the safety and tolerability of Desvenlafaxine SR and Aripiprazole when coadministered to healthy adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 25, 2010
Enrollment StartAug 1, 2010
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.9 years ago

Interventions

Aripiprazoledrug

Period 1-Aripiprazole 5mg on study day 1.

Aripiprazole + desvenlafaxine succinate sustained releasedrug

Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.